

Friday 5th Apr 2024



## CKD drug listed

JARDIANCE (empagliflozin) is now listed on the PBS for Australian patients with chronic kidney disease (CKD) with or without diabetes.

The listing comes off the back of the recent new indication granted by the TGA (*PD* 23 Feb).



#### MedAdvisor Web Solutions

## Digital Grants Now Open

Only 25 Digital
Grants available.

Click for more information or submit your application.



## Student award launched

THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) unveiled a new initiative yesterday recognising the efforts of pharmacy students who are actively building up their professional portfolios.

The announcement, made at the Society of Hospital Pharmacists of Australia's (SHPA) 2024 Student Symposium, in conjunction with the National Australian Pharmacy Students' Association (NAPSA), introduced the inaugural ANZCAP Pharmacy Student of the Year Award, set to be awarded in Sep.

This new accolade is open to pharmacy students nationwide, starting from 01 May, following a comprehensive consultation with NAPSA student members earlier this year.

To be eligible for the award, students need to be enrolled with ANZCAP, a requirement met through the complimentary SHPA student membership.

The award aims to reward pharmacy students who engage in diverse learning experiences, requiring candidates to complete at least six of the 11 dedicated student Learning Experiences offered by ANZCAP.

The winner of the award will receive an all-inclusive trip to

## Savings offer on

NOVA Pharmaceuticals is offering for a limited time a discount on its Restin Melatonin 2mg Modified Release Tablets.

Learn more on the back page.



Adelaide to attend Medicines Management 2024, the country's largest annual scientific pharmacy conference, in Nov.

NAPSA President Bano Serhan expressed enthusiasm for the award, stating, "portfolio-building is quickly becoming a core activity across the next generation of pharmacists in Australia".

"It's a clear way to showcase evidence of your growing skills while mapping a path for your pharmacy career.

"We're pleased to support the ANZCAP Pharmacy Student of the Year award and encourage all NAPSA and SHPA student members to take advantage of their free access to ANZCAP by going into the running when the award opens in May," said Serhan.

This initiative is part of a broader effort to support students pursuing careers in the expanding field of hospital pharmacy in Australia, highlighted by the ongoing partnership between SHPA and NAPSA, which includes the SHPA x NAPSA Student Symposium now in its fifth year. *JG* 

## Today's issue of PD

Pharmacy Daily today features two pages of news, plus a full page from Nova Pharmaceuticals.

## Defective product

THE TGA has alerted pharmacists of a product defect for Fanttest COVID-19/Influenza A&B Antigen Test Kits where the control line appears faint even with strong positive results.

It relates to all ARTG batches numbered 414738 and 395590.



#### **SUPER HYDRATING**

## Probiotic Body Lotion

- Rich moisturising cream
- Improves the skins barrier
- Reduces redness and soothes skin
- Clinically proven
- No Parabens, Petrolatum, SLS



Relieves infant tummy discomfort caused by wind



Active Ingredient: Simethicone 40mg/ml

teva

Always read the label and follow the directions for use. \*IQVIA™ Sell Out Service, Babycare & Accessories, Australia Pharmacy, Total Units Sales, 52WEEK 29/07/2023.



Friday 5th Apr 2024

# LIKE US ON FACEBOOK Pharmacy Daily





## Dispensary Corner

A NEW website called Calmara is promising to help women detect STIs in sexual partners with the help of AI and photos of men's genitals.

It pitches itself as a digital "intimacy bestie", in a move that has everyone from healthcare advocates to privacy experts raising their eyebrows.

The service claims to revolutionise sexual health screening by asking questions and using AI to check uploaded photographic evidence for STIs such as genital warts, herpes eruptions, and syphilis.

But let's rewind to the start of this peculiar tale.

In the not-so-distant past, a company named HeHealth was also offering men quick insights into their downstairs health via AI that could detect signs of STIs with a glance at a photo, boasting 65-96% accuracy.

Fast forward to the present, and Calmara enters.

It's mission?

To allow women to play detective with their potential partners' nether regions, all in the name of STI prevention.

Despite HeHealth attempting to draw a line between Calmara and its parent tech, people raised several privacy concerns as well as doubts around accuracy of results.

After all, both services seem to be cut from the same controversial cloth as they use the same AI.

Both HeHealth and Calmara have admitted in their fine print that maybe, just maybe, their Al's judgement isn't a substitute for a real doctor's advice.

## Pharmacists key to care



A NEW pilot program has revealed that pharmacists are crucial in providing high-quality home-based palliative care to patients, especially in rural settings.

The University of South Australia research, in collaboration with the Pharmaceutical Society of Australia, uncovered significant benefits that pharmacists bring including superior medication management, enhanced communication channels between patients and healthcare providers, and a reduction in the need for general practitioner visits.

Focused on the rural regions of South Australia, the realworld study emphasised the transformative role of pharmacists in easing the journey for patients preferring to spend their final days at home.

With global palliative care needs rising sharply - 56.8 million in need of such care annually, including 25.7 million in the last year of life this research is timely.

Currently, a mere 14% receive palliative care, highlighting a gap that pharmacists are wellpositioned to fill, said the program's lead researcher and pharmacist Tash Downing.

"Our study found that including a pharmacist in the rural palliative care team can help alleviate rural

workforce shortages and improve the quality of care that is available for rural palliative patients," Downing explained.

She added that a locally-based pharmacist provides more choice for palliative patients.

"They can receive trusted care in their own home, they have a local team who can coordinate prescriptions and medications, they don't have to travel as much to appointments, and their level of distress is lower."

This is particularly relevant in rural areas, where healthcare resources are stretched thin.

The pilot program, funded by the South Australian Department for Health and Wellbeing, allowed pharmacists to provide essential care directly to patients at home, showing marked improvements in care quality and accessibility for rural palliative patients.

Dr Gemma Skaczkowski, a co-researcher, noted the pilot program's effectiveness and called for further exploration into sustainable funding and broader implementation of it.

"Our findings underscore the indispensable role of pharmacists in palliative care, promising a better quality of life for patients across the board," Skaczkowski remarked. JG

## Menopause med gains TGA approval

ASTELLA'S Pharma Australia has gained approval for Veoza to treat moderate-tosevere vasomotor symptoms of menopause, such as hot flushes and night sweats.

Veoza distinguishes itself as a once-daily oral pill and is a selective neurokinin 3 receptor antagonist, which moderates the brain's temperature regulation and helps to alleviate symptoms.

The approval stems from the results of the SKYLIGHT 1 and SKYLIGHT 2 Phase 3 studies, showcasing Veoza's efficacy in significantly reducing both the frequency and severity of menopausal symptoms in postmenopausal women.

Within the first four weeks, there was a reduction in symptoms, a trend that continued and improved through the 12 weeks of treatment for participants.

Prof Rodney Baber, from the Royal North Shore Hospital in Sydney, underscored the significance of this development, stating, "approval of Veoza means we can now offer a non-hormonal option that can reduce the frequency and severity of hot flushes and night sweats within one week of starting treatment for some women".

This comment highlights the drug's potential to improve the quality of life for sufferers of menopausal symptoms.

Veoza's introduction into the Australian market follows its approval in other major regions like the United States, the United Kingdom, and by the European Commission.

## **Pharmacy**

#### www.pharmacydaily.com.au

Pharmacy Daily is part of the **Business Publishing Group family** of publications

Pharmacy Daily is Australia's favourite pharmacy industry publication.

#### **EDITORIAL**

Editor - Jayamala Gupte Deputy Editor - Matt Lennon Journalists - Adam Bishop, Myles Stedman, Janie Medbury, Matthew Wai Editor-at-large - Bruce Piper Publisher - Damian Francis

Associate Publisher - Jo-Anne Hui-Miller

#### ADVERTISING AND MARKETING

Head of Sales & Marketing - Sean Harrigan Advertising - Sharad Goodfella & Dante Muranty

advertising@pharmacydaily.com.au

**Head of Operations &** Contributing Editor - Anna Piper

#### **ACCOUNTS**

accounts@traveldaily.com.au

Suite 1, Level 2, 64 Talavera Rd Macquarie Park NSW 2113 Australia Tel: 1300 799 220 (+61 2 8007 6760)

info@pharmacydaily.com.au



Pharmacy Daily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every care has been taken in the preparation of the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Damian Francis.

## Restin, your SLEEP companion

Restin Melatonin 2mg
30 Modified Release Tablets

**Because SLEEP QUALITY matters** 



# Don't sleep on this deal! Limited stock available!

## To order, speak to your Nova Pharmaceuticals TM today on 1300 904 541

Ask your pharmacist—they must decide if this product is right for you. Always read the label. This medicine may not be right for you. Read the warnings before purchase. Follow the directions for use. If symptoms persist talk to your health professional. For the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over. Do not use if: • you are under 55 years of age • you are taking any other medicines for sleep • you have liver problems • you are pregnant or breastfeeding. Unless a doctor has told you to, do not use: • for more than 3 weeks • If you have kidney problems • If you have an autoimmune disease. Consult a pharmacist or doctor before use if you are taking other medicines regularly. Do not drink alcohol while taking this medicine. This medication may cause drowsiness. If affected do not drive or operate machinery. Contains lactose. Adults aged 55 years and over: Take 1 tablet after food, 1-2 hours before you go to bed. Swallow whole. Do not cut, crush or chew. Also contains ammonio methacrylate copolymer type B, calcium hydrogen phosphate, colloidal anhydrous silica, purified talc, magnesium stearate. The full PI is available from Nova Pharmaceuticals Australasia on request.

Please review the full PI before recommending.

Nova Pharmaceuticals Australasia Pty Ltd, Suite 305, 10 Norbrik Drive, Bella Vista, NSW 2153. Tel. 02 8090 7855

Nova Pharmaceuticals – A niche & unique product portfolio delivering a positive contribution to Australian Pharmacies